Financials Pharmaniaga

Equities

End-of-day quote BURSA MALAYSIA Other stock markets 06:00:00 2024-05-22 pm EDT			5-day change	1st Jan Change
0.355 ^MYR	+10.94%		+14.52%	-7.79%

Apr. 19	China's drugmakers can't sell mRNA shots but haven't quit yet	RE
Mar. 27	Pharmaniaga Berhad Appoints Tuan Drs. Imam Fathorrahman as Independent and Non Executive Member of Audit Committee	CI

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025
Capitalization ¹	538.1	1,309	969.4	713.9	554.9	511.6	-
Enterprise Value (EV) ¹	538.1	1,309	969.4	713.9	554.9	511.6	511.6
P/E ratio	-3.6 x	47.6 x	5.63 x	-1.18 x	-6.8 x	11.5 x	11.1 x
Yield	4.13%	2.2%	12.6%	3.49%	-	-	-
Capitalization / Revenue	0.19 x	0.48 x	0.2 x	0.2 x	0.16 x	0.15 x	0.15 x
EV / Revenue	0.19 x	0.48 x	0.2 x	0.2 x	0.16 x	0.15 x	0.15 x
EV / EBITDA	4,120,658 x	12,929,742 x	2,832,310 x	-1,412,926 x	14,141,225 x	-	-
EV / FCF	4.64 x	-31.1 x	-10.3 x	-3.54 x	-59.7 x	22.5 x	-
FCF Yield	21.6%	-3.21%	-9.74%	-28.2%	-1.68%	4.44%	-
Price to Book	1.59 x	3.88 x	2.15 x	-2.87 x	-1.78 x	-2.09 x	-2.54 x
Nbr of stocks (in thousands)	1,306,149	1,308,529	1,309,959	1,309,959	1,441,230	1,441,230	-
Reference price ²	0.4120	1.000	0.7400	0.5450	0.3850	0.3550	0.3550
Announcement Date	2/20/20	3/17/21	2/17/22	2/27/23	2/29/24	-	-

¹MYR in Million²MYR

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025
Net sales ¹	2,821	2,725	4,815	3,511	3,404	3,336	3,503
EBITDA	130.6	101.2	342.3	-505.3	39.24	-	-
EBIT	-153	68.86	308.9	-541.7	-5.106	-	-
Operating Margin	-5.42%	2.53%	6.41%	-15.43%	-0.15%	-	-
Earnings before Tax (EBT) ¹	-191.9	35.79	277.1	-580.8	-62.82	70.7	72.6
Net income ¹	-149.2	27.49	172.2	-607.3	-77.45	45	46.2
Net margin	-5.29%	1.01%	3.58%	-17.3%	-2.28%	1.35%	1.32%
EPS ²	-0.1144	0.0210	0.1315	-0.4636	-0.0566	0.0310	0.0320
Free Cash Flow ¹	116	-42.04	-94.44	-201.6	-9.295	22.7	-
FCF margin	4.11%	-1.54%	-1.96%	-5.74%	-0.27%	0.68%	-
FCF Conversion (EBITDA)	88.83%	-	-	-	-	-	-
FCF Conversion (Net income)	-	-	-	-	-	50.44%	-
Dividend per Share ²	0.0170	0.0220	0.0930	0.0190	-	-	-
Announcement Date	2/20/20	3/17/21	2/17/22	2/27/23	2/29/24	-	-

¹MYR in Million²MYR

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025
Net Debt	-	-	-	-	-	-	-
Net Cash position	-	-	-	-	-	-	-
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-
Free Cash Flow ¹	116	-42	-94.4	-202	-9.3	22.7	-
ROE (net income / shareholders' equity)	-35.2%	8.14%	43.7%	-	-	-	-
ROA (Net income/ Total Assets)	-8.53%	1.73%	8.97%	-29.8%	-4.13%	-	-
Assets ¹	1,750	1,586	1,919	2,038	1,875	-	-
Book Value Per Share ²	0.2600	0.2600	0.3400	-0.1900	-0.2200	-0.1700	-0.1400
Cash Flow per Share	-	-	-	-	-	-	-
Capex	72.7	9.25	30.4	59.3	-	-	-
Capex / Sales	2.58%	0.34%	0.63%	1.69%	-	-	-
Announcement Date	2/20/20	3/17/21	2/17/22	2/27/23	2/29/24	-	-

¹MYR in Million²MYR

Estimates

Trading Rating

Investor Rating

ESG Refinitiv

Sell

Buy

Mean consensus

SELL

Number of Analysts

Last Close Price

0.355 MYR

Average target price

0.31 MYR

Spread / Average Target

-12.68%

	1st Jan change	Capi.
PHARMANIAGA	-7.79%	98.27M
MCKESSON CORPORATION	+21.27%	72.45B
CARDINAL HEALTH, INC.	-4.24%	23.46B
SINOPHARM GROUP CO. LTD.	+4.89%	8.59B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+7.11%	8.35B
HUADONG MEDICINE CO., LTD	-23.73%	7.88B
H. LUNDBECK A/S	+13.92%	5.21B
EBOS GROUP LIMITED	-0.59%	4.11B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	+7.85%	4.09B
CHINA NATIONAL MEDICINES CORPORATION LTD.	+20.65%	3.6B